AARD.OQ - Aardvark Therapeutics Inc
William Blair & Company
CagriSema Did Not Clear Non-Inferiority Bar Against Zepbound; However, No Read-Through to Next-Gen Amylin Class, in Our View
公司
AARD.OQ
日期
2026-02-23
分析师
Andy T. Hsieh, PHD
页数
5 页
需要登录
请登录后购买研报或生成音频内容。